Key result
CRRL269 increases diuresis and sodium excretion with less BP drop than BNP or URO in canines.
Why the study?
The renal protective properties of natriuretic peptides BNP and urodilatin via pGC-A receptor suggest potential for a novel renal-enhancing peptide activator.
Does CRRL269 improve renal function and suppress RAAS with less hypotension compared to BNP or URO in preclinical models?
Population
Human cell lines and normal canines
Comparison
CRRL269 vs BNP and urodilatin
Design
Preclinical acute infusion study
Follow-up
Acute infusion
Authors
Loading...
May warrant further preclinical testing of CRRL269 for cardiorenal benefit; leaves open translation to clinical use.
Does CRRL269 improve renal function and suppress RAAS with less hypotension compared to BNP or URO in preclinical models?
CRRL269 is a novel designer peptide that demonstrates superior renal-enhancing properties and RAAS suppression with less hypotension compared to BNP and URO in preclinical models.
Harty et al. (2017) studied Normal canines and human cell lines (targeting cardiorenal disease). CRRL269 vs. BNP or URO was evaluated on Urinary sodium excretion, diuresis, and blood pressure reduction. CRRL269 exhibited significant and greater increases in urinary sodium excretion and diuresis, with less blood pressure reduction, than BNP or URO in normal canines.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: